プロモーションスケジュール Odonate, Inc.
詳細なスケジュール
簡易グラフ
会社について
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.| IPO date | 2017-12-07 |
|---|---|
| ISIN | US6760791060 |
| Industry | Capital Markets |
| Sector | Financials |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.odonate.com |
| Цена ао | 3380 |
| 月ごとの料金変更: | +0.2933% (17050) |
|---|---|
| 年間の価格変動: | +1 139 900% (1.5) |
| 3年間の価格推移: | +1 147 551.01% (1.49) |
| 5年間の価格推移: | +45 198.01% (37.75) |
| 年初からの価格変動: | +0.2933% (17050) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Boxer Capital, LLC | 4207086 | 14.3 |
| Samsara BioCapital, LLC | 700421 | 2.38 |
| Acadian Asset Management. LLC | 384995 | 1.31 |
| Hennion & Walsh Asset Management, Inc. | 69264 | 0.18 |
| Tower Research Capital LLC (TRC) | 43752 | 0.15 |
| SIMPLEX TRADING, LLC | 2000 | 0.01 |
| BESSEMER GROUP, INCORPORATED | 230 | 0 |
| Newbridge Financial Services Group, Inc. | 47 | 0 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Mr. Kevin C. Tang | Chairman & CEO | 1 | 1967 (58 年) |
| Mr. Michael S. Hearne | CFO & Principal Accounting Officer | 251.23k | 1963 (62 年) |
| Mr. Ryan Cole | Senior Vice President of Operations | N/A | |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations | N/A | 1976 (49 年) |
| Mr. Thomas Wei | Chief Scientific Officer | N/A | 1976 (49 年) |
住所: United States, New York. NY, 3 East 28th Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.odonate.com
Webサイト: https://www.odonate.com
